Evidence map›Paper›PMID 21203539›Full record

ArticlePloS one2010

Inhibitors of foot and mouth disease virus targeting a novel pocket of the RNA-dependent RNA polymerase.

Ryan C Durk, Kamalendra Singh, Ceili A Cornelison, Devendra K Rai, Kayla B Matzek, Maxwell D Leslie, Elizabeth Schafer, Bruno Marchand, Adeyemi Adedeji, Eleftherios Michailidis and 7 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 27 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Anti-foot-and-mouth disease virus effects of Chinese herbal kombucha in vivo.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology]
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Ryan C DurkChristopher Bond Life Sciences Center, Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Columbia, Missouri, United States of America.
Kamalendra Singh
Ceili A Cornelison
Devendra K Rai
Kayla B Matzek
Maxwell D Leslie
Elizabeth Schafer
Bruno Marchand
Adeyemi Adedeji
Eleftherios Michailidis
Christopher A Dorst
Jennifer Moran
Christie Pautler
Luis L Rodriguez
Mark A McIntosh
Elizabeth Rieder
Stefan G Sarafianos
University of Missouri · USUnited States Department of Agriculture · USPlum Island Animal Disease Center · US

Funding

Gene Therapy for HIV Using Aptamers that Target Reverse TranscriptaseR01AI074389 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI BURKE, DONALD H · 2008 to 2017
$4.5M
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIVR01AI076119 · NIAID · UNIVERSITY OF MISSOURI-COLUMBIA · PI SARAFIANOS, STEFAN G · 2008 to 2018
$4.1M
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIVR37AI076119 · NIAID · EMORY UNIVERSITY · PI Stefan G Sarafianos · 2020 to 2026
$3.6M
Microbicide properties of RT inhibitor combinationsR33AI079801 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARNIAK, MICHAEL A · 2010 to 2012
$1.4M
Microbicide properties of RT inhibitor combinationsR21AI079801 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI PARNIAK, MICHAEL A · 2008 to 2009
$421k
NIAID NIH HHS AI074389NIAID NIH HHS AI076119NIAID NIH HHS AI079801NIAID NIH HHS R01 AI074389NIAID NIH HHS R01 AI076119NIAID NIH HHS R21 AI079801NIAID NIH HHS R33 AI079801NIAID NIH HHS R37 AI076119
6 · The paper itself

Abstract

backgroundFoot-and-Mouth Disease Virus (FMDV) is a picornavirus that infects cloven-hoofed animals and leads to severe losses in livestock production. In the case of an FMD outbreak, emergency vaccination requires at least 7 days to trigger an effective immune response. There are currently no approved inhibitors for the treatment or prevention of FMDV infections. METHODOLOGY/PRINCIPAL

findingsUsing a luciferase-based assay we screened a library of compounds and identified seven novel inhibitors of 3Dpol, the RNA-dependent RNA polymerase of FMDV. The compounds inhibited specifically 3Dpol (IC(50)s from 2-17 µM) and not other viral or bacterial polymerases. Enzyme kinetic studies on the inhibition mechanism by compounds 5D9 and 7F8 showed that they are non-competitive inhibitors with respect to NTP and nucleic acid substrates. Molecular modeling and docking studies into the 3Dpol structure revealed an inhibitor binding pocket proximal to, but distinct from the 3Dpol catalytic site. Residues surrounding this pocket are conserved among all 60 FMDV subtypes. Site directed mutagenesis of two residues located at either side of the pocket caused distinct resistance to the compounds, demonstrating that they indeed bind at this site. Several compounds inhibited viral replication with 5D9 suppressing virus production in FMDV-infected cells with EC(50) = 12 µM and EC(90) = 20 µM). SIGNIFICANCE: We identified several non-competitive inhibitors of FMDV 3Dpol that target a novel binding pocket, which can be used for future structure-based drug design studies. Such studies can lead to the discovery of even more potent antivirals that could provide alternative or supplementary options to contain future outbreaks of FMD.

Indexed as

Adenosine TriphosphateAnimalsAntiviral AgentsBinding SitesCatalysisCattleEnzyme InhibitorsFoot-and-Mouth Disease VirusKineticsLigandsLuciferasesModels, ChemicalMutagenesis, Site-DirectedRNA-Dependent RNA PolymeraseVirus ReplicationAdenosine TriphosphateAntiviral AgentsEnzyme InhibitorsLigandsLuciferasesRNA-Dependent RNA Polymerase

Identifiers

PMID21203539
PMCPMC3006429
OpenAlexW2024771806

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.